https://news.smileventurehub.com/ SmiLe newsroom - PressRelease https://news.smileventurehub.com/posts/pressreleases/aventera-secures-funding-to-develop-next-gene Aventera Antibodies has successfully raised SEK 14.5 million in a funding round from Swedish and international investors. The funding will support the preclinical development of the company’s lead drug candidate targeting life-threatening streptococcal infections, with the ambition to enter clinical trials in 2028. https://news.smileventurehub.com/posts/pressreleases/aventera-secures-funding-to-develop-next-gene Tue, 28 Apr 2026 06:05:00 GMT https://news.smileventurehub.com/posts/pressreleases/aventera-sakrar-finansiering-for-att-utveckla Aventera Antibodies har framgångsrikt rest 14,5 miljoner kronor i en finansieringsrunda från svenska och internationella investerare. Kapitalet ska användas för den prekliniska utvecklingen av bolagets ledande läkemedelskandidat mot livshotande streptokockinfektioner, med målet att inleda kliniska studier 2028. https://news.smileventurehub.com/posts/pressreleases/aventera-sakrar-finansiering-for-att-utveckla Tue, 28 Apr 2026 05:50:00 GMT https://news.smileventurehub.com/posts/pressreleases/manje-health-selected-for-mastercard-lighthou Manje Health has been selected to join the prestigious Mastercard Lighthouse MASSIV Programme, a leading initiative supporting fintech companies with solutions that create societal impact. https://news.smileventurehub.com/posts/pressreleases/manje-health-selected-for-mastercard-lighthou Wed, 18 Mar 2026 07:15:00 GMT https://news.smileventurehub.com/posts/pressreleases/manje-health-antaget-till-mastercard-lighthou Manje Health har valts ut till Mastercard Lighthouse MASSIV Programme, ett program som stöttar fintechbolag med lösningar som gör stor skillnad i samhället. https://news.smileventurehub.com/posts/pressreleases/manje-health-antaget-till-mastercard-lighthou Wed, 18 Mar 2026 07:15:00 GMT https://news.smileventurehub.com/posts/pressreleases/students-invited-to-apprenticeship-bootcamp-w SmiLe Venture Hub is launching a new bootcamp on entrepreneurship with focus on working with healthcare as a customer. The Health2Innovation apprenticeship Bootcamp targets international students and doctoral candidates who want to gain practical knowledge about developing digital products and healthtech solutions. https://news.smileventurehub.com/posts/pressreleases/students-invited-to-apprenticeship-bootcamp-w Wed, 25 Feb 2026 07:00:00 GMT https://news.smileventurehub.com/posts/pressreleases/smile-launches-fundament-4-future-an-unpreced SmiLe Venture Hub has launched Fundament 4 Future, an unprecedented project supporting early-stage life science companies in advancing their company-specific development projects. The initiative is carried out in close collaboration with seven incubator member startups from SmiLe’s portfolio. https://news.smileventurehub.com/posts/pressreleases/smile-launches-fundament-4-future-an-unpreced Thu, 05 Feb 2026 10:30:00 GMT https://news.smileventurehub.com/posts/pressreleases/smile-releases-impact-report-2025-highlightin SmiLe releases Impact Report 2025 highlighting a year of strong progress for life science startups https://news.smileventurehub.com/posts/pressreleases/smile-releases-impact-report-2025-highlightin Tue, 03 Feb 2026 10:05:46 GMT https://news.smileventurehub.com/posts/pressreleases/xinnate-meddelar-att-rekryteringen-har-starta Xinnate AB, ett svenskt läkemedelsutvecklingsbolag i klinisk fas som utvecklar nya behandlingar baserade på sin banbrytande peptidteknologi, meddelar idag att det första patientbesöket (FPFV) har genomförts i företagets kliniska fas 2/3-studie med TCP-25 för behandling av Epidermolysis Bullosa (EB). https://news.smileventurehub.com/posts/pressreleases/xinnate-meddelar-att-rekryteringen-har-starta Mon, 02 Feb 2026 10:58:13 GMT https://news.smileventurehub.com/posts/pressreleases/xinnate-announces-that-recruitment-has-starte Xinnate AB, a Swedish clinical-stage drug development company developing novel therapies based on its groundbreaking peptide technology, today announces that the first patient first visit (FPFV) has been completed in the company’s clinical Phase 2/3 study with TCP-25 for the treatment of Epidermolysis Bullosa (EB). https://news.smileventurehub.com/posts/pressreleases/xinnate-announces-that-recruitment-has-starte Mon, 02 Feb 2026 10:55:44 GMT https://news.smileventurehub.com/posts/pressreleases/medvasc-secures-sek-24-million-financing-and MedVasc AB has successfully completed production and testing activities in accordance with its previously communicated plan. In parallel, the company closed a new financing round at the end of 2025, raising SEK 24 million through subscriptions exclusively from existing shareholders. https://news.smileventurehub.com/posts/pressreleases/medvasc-secures-sek-24-million-financing-and Wed, 28 Jan 2026 07:30:00 GMT https://news.smileventurehub.com/posts/pressreleases/medvasc-sakrar-24-miljoner-kronor-i-finansier MedVasc AB har framgångsrikt slutfört produktion och tester enligt tidigare kommunicerad plan. Samtidigt har bolaget genomfört en ny finansieringsrunda och säkrat 24 miljoner kronor för fortsatt utveckling. https://news.smileventurehub.com/posts/pressreleases/medvasc-sakrar-24-miljoner-kronor-i-finansier Wed, 28 Jan 2026 07:20:00 GMT https://news.smileventurehub.com/posts/pressreleases/first-scientific-publication-reporting-clinic Xinnate has publiched its first-in-human, open-label, single-arm clinical study evaluating the safety, tolerability, and systemic exposure of topically applied TCP-25, the company’s novel immunomodulatory peptide, in patients with Epidermolysis Bullosa (EB). https://news.smileventurehub.com/posts/pressreleases/first-scientific-publication-reporting-clinic Mon, 22 Dec 2025 07:15:00 GMT https://news.smileventurehub.com/posts/pressreleases/xinnate-completes-oversubscribed-share-issue Xinnate AB today has completed of an oversubscribed share issue of €3.6 million from existing and new investors. The financing reflects continued confidence in the company’s clinical progress and long-term strategy, including the recently communicated FDA IND approval for a clinical phase 2/3 study. https://news.smileventurehub.com/posts/pressreleases/xinnate-completes-oversubscribed-share-issue Tue, 16 Dec 2025 07:20:00 GMT https://news.smileventurehub.com/posts/pressreleases/xinnate-genomfor-overtecknad-nyemission-om-38 Xinnate AB har genomfört en övertecknad nyemission om 38,5 MSEK. Emissionen väckte starkt intresse från både befintliga och nya investerare, vilket understryker det fortsatta förtroendet för bolagets kliniska utveckling och långsiktiga strategi inklusive det nyligen kommunicerade FDA IND-godkännandet. https://news.smileventurehub.com/posts/pressreleases/xinnate-genomfor-overtecknad-nyemission-om-38 Tue, 16 Dec 2025 07:15:00 GMT https://news.smileventurehub.com/posts/pressreleases/xinnate-far-fda-godkannande-av-ind-for-tcp-25 FDA:s godkännande av Xinnates IND-ansökan för TCP-25 markerar en viktig milstolpe i arbetet med att förbättra behandlingsmöjligheterna för Epidermolysis Bullosa och banar väg för starten av det pivotala fas 2/3-programmet STEP – ett kritiskt steg i bolagets väg mot marknadsgodkännande i USA. https://news.smileventurehub.com/posts/pressreleases/xinnate-far-fda-godkannande-av-ind-for-tcp-25 Tue, 09 Dec 2025 09:18:36 GMT https://news.smileventurehub.com/posts/pressreleases/xinnate-receives-fda-ind-approval-for-tcp-25 Xinnate is taking a major step toward reshaping the treatment landscape for Epidermolysis Bullosa with the FDA’s approval of its IND application for TCP-25 – positioning the company’s lead asset for a pivotal Phase 2/3 program and creating a clear path toward U.S. market entry. https://news.smileventurehub.com/posts/pressreleases/xinnate-receives-fda-ind-approval-for-tcp-25 Tue, 09 Dec 2025 08:28:59 GMT https://news.smileventurehub.com/posts/pressreleases/smile-venture-hub-receives-two-awards-from-th-1 SmiLe Venture Hub has been named one of the winners of the Startup Ecosystem Stars 2025 Awards in two categories: Best-in-class Startup Programs and Outstanding Investment Boost. The awards are presented by the International Chamber of Commerce (ICC) and Mind the Bridge. https://news.smileventurehub.com/posts/pressreleases/smile-venture-hub-receives-two-awards-from-th-1 Wed, 03 Dec 2025 08:12:38 GMT https://news.smileventurehub.com/posts/pressreleases/smile-venture-hub-far-tva-utmarkelser-av-inte SmiLe Venture Hub har utsetts till en av vinnarna av Startup Ecosystem Stars 2025 Awards i två kategorier: Best-in-class Startup Programs och Outstanding Investment Boost. Utmärkelserna delas ut av International Chamber of Commerce (ICC) och Mind the Bridge. https://news.smileventurehub.com/posts/pressreleases/smile-venture-hub-far-tva-utmarkelser-av-inte Wed, 03 Dec 2025 08:00:00 GMT https://news.smileventurehub.com/posts/pressreleases/smile-venture-hub-receives-two-awards-from-th SmiLe Venture Hub has been named one of the winners of the Startup Ecosystem Stars 2025 Awards in two categories: Best-in-class Startup Programs and Outstanding Investment Boost. The awards are presented by the International Chamber of Commerce (ICC) and Mind the Bridge. https://news.smileventurehub.com/posts/pressreleases/smile-venture-hub-receives-two-awards-from-th Wed, 03 Dec 2025 07:58:00 GMT https://news.smileventurehub.com/posts/pressreleases/cirkular-awarded-226-000-to-upcycle-forest-ba After launching its first product this autumn – becoming the first in the world to commercialize mycoprotein for aquaculture – Cirkulär has now been awarded € 226 000 from FORMAS to investigate how additional high-value substances can be obtained through the same process. https://news.smileventurehub.com/posts/pressreleases/cirkular-awarded-226-000-to-upcycle-forest-ba Tue, 02 Dec 2025 09:53:56 GMT https://news.smileventurehub.com/posts/pressreleases/cirkular-far-25-miljoner-kronor-for-att-utvin Efter att i höst ha lanserat sin första produkt – en proteinbaserad ingrediens till fiskfoder framställd från restströmmar i skogsindustrin – har Cirkulär nu, tillsammans med Borås universitet och Kitcoat, beviljats 2,5 MSEK från FORMAS för att undersöka hur fler värdefulla substanser kan utvinnas ur samma process. https://news.smileventurehub.com/posts/pressreleases/cirkular-far-25-miljoner-kronor-for-att-utvin Tue, 02 Dec 2025 09:37:44 GMT https://news.smileventurehub.com/posts/pressreleases/cytely-ab-raises-capital-to-accelerate-discov Cytely has raised €3 million in a funding round led by Danish Ugly Duckling Ventures. The new capital will be used to support international expansion of the company’s AI-driven microscopy platform, which automates cell analysis and accelerates biomedical research. https://news.smileventurehub.com/posts/pressreleases/cytely-ab-raises-capital-to-accelerate-discov Wed, 22 Oct 2025 13:12:22 GMT https://news.smileventurehub.com/posts/pressreleases/cytely-ab-reser-kapital-for-att-paskynda-uppt Cytely tar in 3 miljoner euro, runt 33 miljoner kronor, i en finansieringsrunda ledd av danska Ugly Duckling Ventures. Kapitalet ska användas för en internationell expansion av företagets AI-drivna mikroskopiplattform, som automatiserar cellanalyser och snabbar upp biomedicinsk forskning. https://news.smileventurehub.com/posts/pressreleases/cytely-ab-reser-kapital-for-att-paskynda-uppt Wed, 22 Oct 2025 12:24:45 GMT https://news.smileventurehub.com/posts/pressreleases/immunebiotech-starker-sin-position-forsknings SmiLes alumnibolag ImmuneBiotech Medical Sweden AB i Lund tar nästa steg i sin tillväxtresa när den forskningsbaserade precisionsprobiotikan GutMagnific® nu finns tillgänglig via Apoteket AB:s webbshop. https://news.smileventurehub.com/posts/pressreleases/immunebiotech-starker-sin-position-forsknings Tue, 21 Oct 2025 13:37:02 GMT https://news.smileventurehub.com/posts/pressreleases/promising-results-for-lead-biologics-first-in Lead Biologics, a company in SmiLe's incubator program, takes a major step towards a new cancer treatment. A new study shows that the company’s drug candidate effectively inhibits a previously unknown immune escape mechanism and eliminates acute myeloid leukemia cells in advanced experimental models. https://news.smileventurehub.com/posts/pressreleases/promising-results-for-lead-biologics-first-in Mon, 06 Oct 2025 06:30:00 GMT https://news.smileventurehub.com/posts/pressreleases/lovande-resultat-for-lead-biologics-lakemedel SmiLe-bolaget Lead Biologics tar avgörande steg mot en ny cancerbehandling. En ny studie visar att bolagets läkemedelskandidat effektivt blockerar en tidigare okänd mekanism som cancerceller använder för att undgå immunförsvaret. Detta gör att antikroppen kan eliminera cancerceller i avancerade experimentella modeller av akut myeloisk leukemi. https://news.smileventurehub.com/posts/pressreleases/lovande-resultat-for-lead-biologics-lakemedel Mon, 06 Oct 2025 06:30:00 GMT https://news.smileventurehub.com/posts/pressreleases/a-successful-year-of-collaboration-abbvie-gol The one-year AbbVie Golden Ticket program has officially concluded – marking the end of a highly successful collaboration between AbbVie, SmiLe Venture Hub, and AAX Biotech, the winning startup of 2024. https://news.smileventurehub.com/posts/pressreleases/a-successful-year-of-collaboration-abbvie-gol Wed, 18 Jun 2025 09:48:28 GMT https://news.smileventurehub.com/posts/pressreleases/xinnate-announces-successful-fda-meeting-for Xinnate AB, a clinical-stage company focused on developing treatments for patients with Epidermolysis Bullosa (EB), today announced that positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA): the upcoming study is now being upgraded to serve as a registrational trial. https://news.smileventurehub.com/posts/pressreleases/xinnate-announces-successful-fda-meeting-for Tue, 20 May 2025 06:30:00 GMT https://news.smileventurehub.com/posts/pressreleases/xinnate-tillkannager-lyckat-fda-mote-for-tcp- Xinnate AB, som utvecklar behandlingar för patienter med Epidermolysis Bullosa (EB), har fått positiv återkoppling från sitt Type C-möte med amerikanska läkemedelsmyndigheten FDA (U.S. Food and Drug Administration): den kommande kliniska studien uppgraderas för att kunna ligga till grund för en registreringsansökan. https://news.smileventurehub.com/posts/pressreleases/xinnate-tillkannager-lyckat-fda-mote-for-tcp- Tue, 20 May 2025 06:10:00 GMT https://news.smileventurehub.com/posts/pressreleases/medvasc-raises-sek-10-million-to-accelerate-f MedVasc AB has successfully closed a SEK 10 million financing round. The funding supports the company’s final product development phase and preparation for FDA regulatory approval in the United States. https://news.smileventurehub.com/posts/pressreleases/medvasc-raises-sek-10-million-to-accelerate-f Fri, 16 May 2025 07:47:45 GMT https://news.smileventurehub.com/posts/pressreleases/medvasc-tar-in-10-msek-for-att-accelerera-slu MedVasc har framgångsrikt genomfört en finansieringsrunda på 10 miljoner kronor. Kapitalet kommer att användas för att stödja företagets slutliga produktutvecklingsfas samt förberedelser inför regulatoriskt godkännande i USA. https://news.smileventurehub.com/posts/pressreleases/medvasc-tar-in-10-msek-for-att-accelerera-slu Fri, 16 May 2025 07:42:08 GMT https://news.smileventurehub.com/posts/pressreleases/reccan-ab-secures-sek-7-million-investment-to RECCAN AB has secured SEK 7 million through a directed share issue, with Sandberg Development as the lead investor. The capital will fund clinical validation and verification of production processes ahead of CE marking and a European launch. https://news.smileventurehub.com/posts/pressreleases/reccan-ab-secures-sek-7-million-investment-to Tue, 06 May 2025 06:20:00 GMT https://news.smileventurehub.com/posts/pressreleases/reccan-ab-sakrar-7-miljoner-kronor-for-att-ta RECCAN AB har säkrat 7 miljoner kronor genom en riktad nyemission, där Sandberg Development är största investerare. Kapitalet kommer att finansiera klinisk validering och verifiering av produktionsprocesser inför CE-märkning och lansering i Europa. https://news.smileventurehub.com/posts/pressreleases/reccan-ab-sakrar-7-miljoner-kronor-for-att-ta Tue, 06 May 2025 06:10:00 GMT https://news.smileventurehub.com/posts/pressreleases/smile-starker-global-innovation-inom-life-sci SmiLe Venture Hub bidrar till utvecklingen och lanseringen av den nya OYSTER-inkubatorn, som har skapats för att påskynda innovation inom hälsa och life science i Finland. https://news.smileventurehub.com/posts/pressreleases/smile-starker-global-innovation-inom-life-sci Mon, 14 Apr 2025 10:05:00 GMT https://news.smileventurehub.com/posts/pressreleases/smile-strengthens-global-life-science-innovat SmiLe Venture Hub is supporting the development and launch of the new OYSTER Incubator, designed to accelerate health and life science innovation in Finland. https://news.smileventurehub.com/posts/pressreleases/smile-strengthens-global-life-science-innovat Mon, 14 Apr 2025 10:05:00 GMT https://news.smileventurehub.com/posts/pressreleases/capillon-analytics-paves-the-way-for-early-ca The new SmiLe company Capillon Analytics is developing an innovative method for early cancer detection based on hair analysis. Using an AI-driven technology that identifies chemical signatures in hair strands, their method has the potential to revolutionize early detection of cancer. https://news.smileventurehub.com/posts/pressreleases/capillon-analytics-paves-the-way-for-early-ca Mon, 31 Mar 2025 09:50:00 GMT https://news.smileventurehub.com/posts/pressreleases/capillon-analytics-banar-vag-for-tidig-cancer Det nya SmiLe-bolaget Capillon Analytics utvecklar en innovativ metod för tidig upptäckt av cancer baserad på håranalys. Med hjälp av en AI-driven teknik som identifierar kemiska signaturer i hårstrån kan deras metod revolutionera cancerdiagnostiken. https://news.smileventurehub.com/posts/pressreleases/capillon-analytics-banar-vag-for-tidig-cancer Mon, 31 Mar 2025 09:40:00 GMT https://news.smileventurehub.com/posts/pressreleases/nya-smile-bolaget-strike-pharma-utvecklar-ban Strike Pharma är antaget till SmiLes inkubatorprogram. Bolaget har tagit fram en teknologiplattform som gör det möjligt att selektivt leverera läkemedel inneslutna i nanopartiklar till olika celler i kroppen.Med bolagets innovation kan immunceller programmeras om inne i kroppen (in vivo). https://news.smileventurehub.com/posts/pressreleases/nya-smile-bolaget-strike-pharma-utvecklar-ban Thu, 27 Mar 2025 10:55:00 GMT https://news.smileventurehub.com/posts/pressreleases/new-smile-company-strike-pharma-develops-next New SmiLe company Strike Pharma has developed a technology platform that enables the selective delivery of drugs, enclosed in nanoparticles, to specific cells in the body. With this innovation, immune cells can be reprogrammed inside the body (in vivo). https://news.smileventurehub.com/posts/pressreleases/new-smile-company-strike-pharma-develops-next Thu, 27 Mar 2025 10:05:00 GMT https://news.smileventurehub.com/posts/pressreleases/zeiss-becomes-a-new-lab-partner-for-smile-ven SmiLe has entered into a partnership with Zeiss, a leading company in the development, manufacturing, and marketing of optical instruments. Zeiss has delivered three new microscopes and upgraded several existing ones. https://news.smileventurehub.com/posts/pressreleases/zeiss-becomes-a-new-lab-partner-for-smile-ven Fri, 14 Feb 2025 07:20:00 GMT https://news.smileventurehub.com/posts/pressreleases/zeiss-blir-ny-labbpartner-till-smile-venture SmiLe har ingått ett partnerskap med Zeiss, ett ledande företag inom utveckling, tillverkning och marknadsföring av optiska instrument. Zeiss har levererat tre nya mikroskop och uppgraderat ett antal befintliga mikroskop. https://news.smileventurehub.com/posts/pressreleases/zeiss-blir-ny-labbpartner-till-smile-venture Fri, 14 Feb 2025 07:10:00 GMT https://news.smileventurehub.com/posts/pressreleases/new-technology-from-emulsi-biotech-can-make-b The new SmiLe company Emulsi Biotech is developing a groundbreaking platform technology for the oral delivery of drugs. Their innovative NanoLIPID platform has the potential to protect drug substances, enable slow release, and significantly enhance the body's absorption of medications. https://news.smileventurehub.com/posts/pressreleases/new-technology-from-emulsi-biotech-can-make-b Thu, 06 Feb 2025 11:20:00 GMT https://news.smileventurehub.com/posts/pressreleases/ny-teknik-fran-emulsi-biotech-kan-gora-biolog Emulsi Biotech utvecklar en banbrytande plattformsteknik för administrering av orala läkemedel. Deras innovativa NanoLIPID-plattform har potential att kunna skydda läkemedelssubstanser, ge en långsam frisättning och avsevärt förbättra kroppens upptag av läkemedel. https://news.smileventurehub.com/posts/pressreleases/ny-teknik-fran-emulsi-biotech-kan-gora-biolog Thu, 06 Feb 2025 07:30:00 GMT https://news.smileventurehub.com/posts/pressreleases/smile-venture-hub-takes-a-role-in-shaping-the We are join forces with seven prominent European agri-foodtech innovation clusters in the project to accelerate the deployment of emerging technologies in cellular agriculture https://news.smileventurehub.com/posts/pressreleases/smile-venture-hub-takes-a-role-in-shaping-the Wed, 29 Jan 2025 14:09:00 GMT https://news.smileventurehub.com/posts/pressreleases/smile-inject-capital-invests-3-million-sek-in Medical technology company Xaga Surgical raises a total of 8 million SEK in an investment round, with SmiLe Inject Capital contributing 3 million SEK. Xaga Surgical develops innovative medical needles to reduce the risk of infections and improve cancer diagnostics. https://news.smileventurehub.com/posts/pressreleases/smile-inject-capital-invests-3-million-sek-in Fri, 24 Jan 2025 09:25:39 GMT https://news.smileventurehub.com/posts/pressreleases/smile-inject-capital-investerar-3-miljoner-kr SmiLe Inject Capital investerar 3 miljoner kronor i Xaga Surgical, ett medicinteknikbolag som utvecklar innovativa medicinska nålar för att minska risken för infektioner och förbättra cancerdiagnostik. Investeringsrundan uppgår till totalt 8 miljoner kronor. https://news.smileventurehub.com/posts/pressreleases/smile-inject-capital-investerar-3-miljoner-kr Fri, 24 Jan 2025 09:13:47 GMT https://news.smileventurehub.com/posts/pressreleases/xinnate-receives-orphan-drug-designation-from Xinnate receives Orphan Drug Designation from US FDA for TCP-25, the company's drug candidate for the treatment of the severe disease Epidermolysis Bullosa (EB). https://news.smileventurehub.com/posts/pressreleases/xinnate-receives-orphan-drug-designation-from Tue, 14 Jan 2025 07:20:00 GMT https://news.smileventurehub.com/posts/pressreleases/xinnate-far-sarlakemedelsstatus-fran-amerikan Den amerikanska läkemedelsmyndigheten (FDA) har beviljat särläkemedelsstatus (Orphan Drug Designation, ODD) för Xinnates läkemedelskandidat TCP-25 för behandling av Epidermolysis Bullosa (EB), en svår genetisk sjukdom. https://news.smileventurehub.com/posts/pressreleases/xinnate-far-sarlakemedelsstatus-fran-amerikan Tue, 14 Jan 2025 07:15:00 GMT https://news.smileventurehub.com/posts/pressreleases/bio-rad-joins-smile-venture-hub-as-new-lab-pa Bio-Rad joins SmiLe Venture Hub as new lab partner. Through this partnership, Bio-Rad’s state-of-the-art QX600™ AutoDG Droplet Digital PCR System is now available to companies using SmiLe’s laboratories in Lund. https://news.smileventurehub.com/posts/pressreleases/bio-rad-joins-smile-venture-hub-as-new-lab-pa Fri, 10 Jan 2025 07:35:00 GMT https://news.smileventurehub.com/posts/pressreleases/bio-rad-blir-ny-labbpartner-till-smile-ventur Bio-Rad blir ny labbpartner till SmiLe Venture Hub. Genom detta partnerskap är Bio-Rads toppmoderna QX600™ AutoDG Droplet Digital PCR System nu tillgängligt för företag som använder SmiLes laboratorier i Lund. https://news.smileventurehub.com/posts/pressreleases/bio-rad-blir-ny-labbpartner-till-smile-ventur Fri, 10 Jan 2025 07:15:00 GMT